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comoribidity burden than age- and gender-matched controls, and
incur much higher levels of inpatient service use and overall
health care costs.
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OBJECTIVES: GAD is a chronic psychiatric disorder with an
estimated lifetime prevalence of 5.7% in the U.S. population.
This study evaluated the health care costs and utilization pat-
terns for individuals with GAD in the U.S. METHODS: A large,
geographically-representative aggregated medical and pharmacy
claims database from the UnitedHealth Group was used to con-
struct the study database. The database included approximately
1.4 million covered lives, from May 2000 through July 2005.
Individuals were extracted who had at least one ICD-9 code of
300.02 for GAD. The date of ﬁrst GAD claim was deﬁned as the
index date. Individuals were excluded if not enrolled for at least
six months prior to and 12 months after the index date. Costs
were reported in both nominal and constant dollars (in 2005
dollars). RESULTS: After applying the exclusion/exclusion 
criteria, the study sample included 101,367 eligible individuals
with GAD; 65% were female and average age was 39.7 years.
On average, annual total non-drug medical costs for an individ-
ual with GAD were $6,585 ($8,864 in constant dollars) prior to
the index date and increased to $9,562 ($10,904), or 45%, in
the post-index date period. Annual total costs for all prescrip-
tions increased from $1212 ($1314) in the pre-index date period
to $1959 ($2018), or 62%, in the post-index date period. On
average, 19 and 24 prescriptions were ﬁlled per year in the 
pre- and post-index periods, respectively. Most prescribed mental
disorder drugs were antidepressants, followed by anxiolytics 
and anticonvulsants. CONCLUSIONS: Individuals with GAD
consume enormously high health care services before and after
GAD diagnosis, and health care expenditures increase signiﬁ-
cantly after GAD is diagnosed. Further research is warranted 
to investigate how cost and utilization patterns relate to factors
such as demographic and clinical characteristics to better 
understand costs and implications of GAD to both patients and
society.
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Despite the clinical and economic importance of depression,
resource utilization and cost in clinical practice is not well doc-
umented. OBJECTIVES: The aim of this study was to investi-
gate medical resource consumption, productivity loss and costs
associated with patients treated with antidepressants for depres-
sion in primary care. METHODS: A total of 447 patients were
enrolled at 56 Swedish primary care centres to this naturalistic
longitudinal observational study. Patients over 18 years with
depressive symptoms, and who initiated a new antidepressant
therapy were included in the study. Data on patients’ socio-
demographics, daily activity and quality-of-life (EQ-5D) were
collected using questionnaires completed during outpatient GP
visit for a follow-up period of approximately 6 months.
RESULTS: Based on a complete sample of 398 patients, the total
annual cost per patient was estimated at $13,400 (SEK 12,300–
$15,100) in 2005 prices. Direct costs were estimated at $4800
($4300–$5400), constituting 35% of the total annual cost per
patient. Among direct costs, the cost for medical visits was the
largest single cost item, representing about 18%. The costs for
antidepressants represented only 4% of the total costs. The indi-
rect costs, i.e. productivity loss due to lost working time, were
estimated at $9000 per patient ($7600–10,200), or 65% of the
total annual costs per patient. No demographic variables were
signiﬁcantly associated with cost of depression. Direct and indi-
rect costs were however correlated positively with achievement
of clinical remission. The presence of sick-leave during follow-
up was moreover associated with 1.8 times higher costs. CON-
CLUSIONS: The burden of depression to society is high, both
in terms of direct treatments costs and indirect costs for sickness
absence and early retirement. Because of the high indirect cost
per patient, there seems to be a particular need for therapies that
have the potential to reduce absenteeism.
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OBJECTIVES: The study examines patterns of antidepressant
use including drug switching and related resource utilization.
METHODS: Using retrospective claims of managed care
enrollees from a national database (PharMetrics), this study fol-
lowed newly diagnosed depression patients (age 18+) with newly
prescribed antidepressants. Patients switching from commonly
prescribed selective serotonin reuptake inhibitors (SSRIs; ﬂuox-
etine, citalopram, sertraline, and paroxetine) to serotonin-
norepinephrine reuptake inhibitors (SNRI; venlafaxine), and vice
versa were identiﬁed and quantiﬁed. The healthcare costs for a
1-year period following diagnosis for various switcher groups
were then aggregated. Multivariate regression analyses were used
to determine the predictors of switching and the factors inﬂu-
encing overall and depression-related costs while controlling for
confounding factors. RESULTS: Of the 48,950 patients included
in the study population, 89% were treated with SSRIs and 11%
with SNRIs. Twelve percent to 15% of patients switched anti-
depressants. Of the SSRI switchers, 29% switched to an SNRI.
Increased likelihood of switching was associated with female
gender, Medicaid coverage, prior anxiolytic use, treatment by a
psychiatrist or psychologist, and paroxetine as the index med-
ication. Compared with SSRI non-switchers, costs for SSRI
switchers were 36% higher for all causes and 58% higher for
depression-related causes. In contrast, compared with SNRI 
non-switchers, costs for SNRI switchers were 27% higher for all
causes and 5% higher for depression-related causes. Thus,
patients switching from SSRI to SNRI are accruing relatively
greater costs than vice versa. In addition, among SSRI patients
switching to SNRI, costs increased with the number of switches.
Mutlivariate analyses conﬁrmed that switching was associated
with higher overall and depression-related costs. CONCLU-
SIONS: Switching among antidepressants is quite frequent
among depression patients. Switchers incur signiﬁcantly higher
overall and depression-related costs, and in general, switching
antidepressants is more costly for SSRI patients than for SNRI
patients.
